Tag:

Roche

Latest Headlines

Latest Headlines

Turkish man sent to prison for smuggling fake Avastin into U.S.

A Turkish man who admitted to smuggling counterfeit cancer drugs to the U.S. labeled as gifts or documents has been sentenced to 27 months in federal prison.

More heat applied to Genentech CEO for supply-chain decision on cancer drugs

Genentech CEO Ian Clark is again being publicly chastised for his company's decision to move three of its best-selling cancer drugs to specialty distributors. Groups representing more than 5,000 hospitals say, besides higher costs, the move is as likely to encourage counterfeiting as to deter it.

Roche, too, has big plans for improved HQ facilities

Swiss drugmaker Roche has plans for a big overhaul of its corporate headquarters. The drugmaker will spend about 3 billion Swiss francs ($3.2 billion) on a renovation that will add new labs and offices, and upgrade existing buildings on its Basel, Switzerland-based site.

Cancer survivor's petition pleads with Roche for lower Kadcyla price

Drugmakers are accustomed to grappling with government payers and PBMs over prices. But a pricing fight directly with patients? That's not your everyday occurrence.

Roche blueprints a sprawling $1.8B R&D complex for pRED

They're building a new home for John Reed and Roche's pRED research group in Basel--and the pharma giant is thinking big. Roche said today that it is committing $1.8 billion to build a new research center in Switzerland that will encompass four new office and lab buildings to house 1,900 R&D staffers.

Roche plots $3.2B overhaul at Basel HQ, joining parade of Big Pharma building projects

Following the lead of other Big Pharma heavyweights, Roche is giving its corporate headquarters a facelift. The drugmaker will funnel 3 billion Swiss francs into a renovation project to upgrade its existing facilities and to add new buildings to its Basel, Switzerland-based site.

Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF

When it comes to the makings of a market-share showdown, the idiopathic pulmonary fibrosis (IPF) landscape has it all. Same-day FDA approvals? Check. A patient population never before reached by pharma? Check. Nearly identical price tags? As of this week, that's a check, too.

Regeneron's Eylea bests Lucentis, Avastin in diabetic eye disease, NIH study finds

Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.

Roche taps DKSH to move its products in Asia

DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.

Top 10 Phase III disasters of 2014

Welcome to the hall of shame, where blockbuster drug projections go to die. This list includes some drugs that clearly should never have wound up in Phase III to begin with, a few that were steered back to the clinic in a doomed attempt to mine something positive, and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology.